Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental pill tested against seven rare blood diseases

NCT ID NCT00255346

Summary

This study tested whether an oral medication called dasatinib could help control several rare blood cancers and disorders. Sixty-eight adults with conditions like acute myeloid leukemia, myelofibrosis, and mastocytosis took the pill daily for as long as it worked. Researchers measured if the drug reduced disease markers and monitored side effects to see if it was safe and effective.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPEREOSINOPHILIC SYNDROME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.